Cargando…

Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma

Aim: Despite aggressive multiagent protocols, patients with metastatic rhabdomyosarcoma (RMS) have poor prognosis. In a recent high-risk trial (ARST0431), 25% of patients failed within the first year, while on therapy and 80% had tumor progression within 24 months. However, the mechanisms for tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghilu, Samson, Morton, Christopher L., Vaseva, Angelina V., Zheng, Siyuan, Kurmasheva, Raushan T., Houghton, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992598/
https://www.ncbi.nlm.nih.gov/pubmed/35450020
http://dx.doi.org/10.20517/cdr.2021.112